UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD
MYLAN PHARMACEUTICALS, INC.
Petitioner
v.
YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Patent Owner
Case No. IPR2015-00644 Patent No. 8,399,413

YEDA'S PRELIMINARY PATENT OWNER RESPONSE



Table of Contents

				<u>Page</u>		
I.	INTI	RODUCTIO	N	1		
II.	THE	'413 PATE	NT	6		
III.	BACKGROUND FACTS			9		
	A.	Multiple Sclerosis				
	B. COPAXONE® - Glatiramer Acetate			11		
		1.	The Active Molecule In GA Is Unknown	11		
		2.	GA's Mechanism Of Action Is Unknown	13		
		3.	No PK/PD Correlation Exists For GA	15		
IV.	THE	PRIOR AR	Γ	17		
V.	MYI	LAN'S PROI	FFERED GROUNDS OF UNPATENTABILITY	23		
VI.			POSED CONSTRUCTION OF "COMPRISING" IS LE AND SHOULD BE REJECTED			
	A.	Yeda Expressly Disclaimed Coverage of Alternate Day Administration During Prosecution				
	B.	Mylan's Proposed Claim Construction Conflicts With The Intrinsic Record				
	C.	-	ng" Should Not be Interpreted to Render the "Regimep Open-Ended.			
VII.	MYI		PETITION SHOULD BE REJECTED			
	A.		Fails: Pinchasi Does Not Anticipate Claims 1-6 And			
	В.	Grounds 2, 3, And 4 Fail: The Claims Would Not Have Been C Over Pinchasi Alone Or Pinchasi In View Of The SBOA Or Fl				
		1.	Mylan's Definition Of The Person Of Ordinary Sk Should Be Rejected	ill		
		2.	A POSA Would Not Have Had A Reasonable Expectation Of Success In Using A 40 mg Three The Per Week Regimen Because The Active Molecule Mechanism Of Action Were Unknown, And There No PK/PD Correlation	And Was		



Case No. IPR2015-00503 Yeda's Preliminary Response

		3.	A Skilled Artisan Would Not Have Been Motivated To Dose GA Three Times Weekly	
		4.	It Would Not Have Been Obvious To Use A 40 mg Do	
		5.	The Person of Skill Would Not Have Been Motivated t Combine Pinchasi with the SBOA And/Or Flechter	
		6.	Mylan Has Failed To Prove That The SBOA Documen Is Available As Prior Art	
VIII.			UTED, IT SHOULD NOT BE INSTITUTED FOR ALL	
	A.	The Board Should Not Institute Review Of Dependent Claims 6-7 And 14-18 Where Mylan's Only Argument Is An Insufficiently Supported Assertion That The Claim Limitations Are "Inherent" In The Prior Art		
	B.	The Board S	Should Not Institute Review Of Claim 7	.53
IX.			ESULTS AND OBJECTIVE INDICIA SUPPORT THE Y OF THE '413 PATENT CLAIMS	
	A.	Unexpected Results Support The Patentability Of The '413 Patent's Claims54		
	B.		Success Supports The Patentability Of The '413 Patent	
	C.	The Claime	d Invention Met A Long Felt But Unmet Need	.56
\mathbf{v}	COM	CLUSION		50



TABLE OF AUTHORITIES

	Page(s)
Cases	
Cedarapids, Inc. v. Nordberg, Inc., No. 95-1529, 1997 WL 452801 (Fed. Cir. Aug. 11, 1997)	35
Dippin' Dots, Inc. v. Mosey, 476 F.3d 1337 (Fed. Cir. 2007)	28
Elkay Mfg. Co. v. Ebco Mfg. Co., 192 F.3d 973 (Fed. Cir. 1999)	27
ERBE Elektromedizin GmbH v. Canady Tech. LLC, 629 F.3d 1278 (Fed. Cir. 2010)	26
Ericsson, Inc. v. D-Link Sys., Inc., 773 F.3d 1201 (Fed. Cir. 2014)	32
In re Fritch, 972 F.2d 1260 (Fed. Cir. 1992)	40
Gillette Co. v. Energizer Holdings, Inc., 405 F.3d 1367 (Fed. Cir. 2005)	30, 31
Hoffmann-La Roche Inc. v. Apotex Inc., 748 F.3d 1326 (Fed. Cir. 2014)	37, 38
Interconnect Planning Corp. v. Feil, 774 F.2d 1132 (Fed. Cir. 1985)	46, 47
Leo Pharm. Prods., Ltd. v. Rea, 726 F.3d 1346 (Fed. Cir. 2013)	37
Mass. Inst. of Tech. v. Harman Int'l Indus., 584 F. Supp. 2d 297 (D. Mass. 2008)	48
In re McLaughlin, 443 F.2d 1392 (C.C.P.A. 1971)	56
<i>In re Robertson</i> , 169 F.3d 743 (Fed. Cir. 1999)	



Spectrum Int'l, Inc. v. Sterilite Corp., 164 F.3d 1372 (Fed. Cir. 1998)	29
SRI Int'l Inc. v. Internet Sec. Sys., Inc. et al., 511 F.3d 1186 (Fed. Cir. 2008)	49, 50
Std. Oil Co. v. Am. Cyanamid Co., 774 F.2d 448 (Fed. Cir. 1985)	27
Syntex (U.S.A.) LLC v. Apotex Inc., No. C 01-02214 MJJ, 2006 WL 1530101 (N.D. Cal. June 2, 2006)	56
<i>U.S. v. Telectronics, Inc.</i> , 857 F.2d 778 (Fed. Cir. 1988)	35
Unigene Labs., Inc. v. Apotex, Inc., 655 F.3d 1352 (Fed. Cir. 2011)	36
VirnetX, Inc. v. Cisco Sys., Inc., 767 F.3d 1308 (Fed. Cir. 2014)	32
W.L. Gore & Assocs., Inc. v. Garlock, Inc., 721 F.2d 1540 (Fed. Cir. 1983)	40
Warner Chilcott Co., LLC v. Teva Pharms. USA, Inc., 594 Fed. Appx. 630 (Fed. Cir. Nov. 18, 2014)	37, 38
<i>Zhejiang Med. Co. v. Kaneka Corp.</i> , No. H-11-1052, 2012 WL 4795623 (S.D. Tex. Aug. 23, 2012)	29
Statutes	
35 U.S.C. §102	passim
35 U.S.C. §312(a)(3)	50
Other Authorities	
M P F P 82141 03(I)	35



DOCKET A L A R M

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

